BioCentury | Aug 29, 2020
Deals

Data Bytes: Cryoport deals show continued interest in cell, gene therapy manufacturing and supply chain players

...and manufacturing acquisitions.  Among the largest was the $2.1 billion acquisition of viral vector manufacturer Brammer Bio...
...Therapy Shipper product line. Amanda Micklus Spark Therapeutics Celgene Corp. Juno Therapeutics Inc. Sorrento Therapeutics Inc. SmartPharm Therapeutics Inc. Thermo Fisher Scientific Inc. Brammer Bio Merck...
BioCentury | Jul 1, 2019
Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

...Amicus picks Brammer as gene therapy manufacturer Amicus Therapeutics Inc. (NASDAQ:FOLD) has partnered with the Brammer Bio...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...March, Thermo Fisher Scientific Inc. acquired gene and cell therapy contract development and manufacturing company Brammer Bio...
BioCentury | Apr 15, 2019
Company News

$1.2B Catalent-Paragon deal latest in race to lock up gene therapy manufacturing

...Inc. (NYSE:TMO) paid $1.7 billion for gene and cell therapy contract development and manufacturing company Brammer Bio...
...in 2019 revenue Thermo expects Brammer to generate (see “Thermo Fisher Buying Gene Therapy Manufacturer Brammer Bio”...
BioCentury | Mar 25, 2019
Company News

Thermo Fisher buying gene therapy manufacturer Brammer Bio

...will pay $1.7 billion to acquire gene and cell therapy contract development and manufacturing company Brammer Bio...
...said Brammer Bio (Cambridge, Mass.) is likely to generate $250 million in 2019 revenue. Since 2017, Brammer Bio...
...Abeona Therapeutics Inc. (NASDAQ:ABEO), all of whom have gene therapy products in clinical development. A Brammer Bio...
BioCentury | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

...capabilities is the best scenario in our mind.” Richard Snyder, CSO of gene therapy CMO Brammer Bio...
...data may be sufficient to support a launch in the rare disease space,” he said. Brammer Bio...
...Calif. Audentes Therapeutics Inc. (NASDAQ:BOLD), San Francisco, Calif. BioProcess Technology Consultants Inc. (BPTC), Woburn, Mass. Brammer Bio...
Items per page:
1 - 6 of 6
BioCentury | Aug 29, 2020
Deals

Data Bytes: Cryoport deals show continued interest in cell, gene therapy manufacturing and supply chain players

...and manufacturing acquisitions.  Among the largest was the $2.1 billion acquisition of viral vector manufacturer Brammer Bio...
...Therapy Shipper product line. Amanda Micklus Spark Therapeutics Celgene Corp. Juno Therapeutics Inc. Sorrento Therapeutics Inc. SmartPharm Therapeutics Inc. Thermo Fisher Scientific Inc. Brammer Bio Merck...
BioCentury | Jul 1, 2019
Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

...Amicus picks Brammer as gene therapy manufacturer Amicus Therapeutics Inc. (NASDAQ:FOLD) has partnered with the Brammer Bio...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...March, Thermo Fisher Scientific Inc. acquired gene and cell therapy contract development and manufacturing company Brammer Bio...
BioCentury | Apr 15, 2019
Company News

$1.2B Catalent-Paragon deal latest in race to lock up gene therapy manufacturing

...Inc. (NYSE:TMO) paid $1.7 billion for gene and cell therapy contract development and manufacturing company Brammer Bio...
...in 2019 revenue Thermo expects Brammer to generate (see “Thermo Fisher Buying Gene Therapy Manufacturer Brammer Bio”...
BioCentury | Mar 25, 2019
Company News

Thermo Fisher buying gene therapy manufacturer Brammer Bio

...will pay $1.7 billion to acquire gene and cell therapy contract development and manufacturing company Brammer Bio...
...said Brammer Bio (Cambridge, Mass.) is likely to generate $250 million in 2019 revenue. Since 2017, Brammer Bio...
...Abeona Therapeutics Inc. (NASDAQ:ABEO), all of whom have gene therapy products in clinical development. A Brammer Bio...
BioCentury | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

...capabilities is the best scenario in our mind.” Richard Snyder, CSO of gene therapy CMO Brammer Bio...
...data may be sufficient to support a launch in the rare disease space,” he said. Brammer Bio...
...Calif. Audentes Therapeutics Inc. (NASDAQ:BOLD), San Francisco, Calif. BioProcess Technology Consultants Inc. (BPTC), Woburn, Mass. Brammer Bio...
Items per page:
1 - 6 of 6